Visualization and Analysis of Parkinson’s Disease Status and Therapy Patterns

  • Anita ValmarskaEmail author
  • Dragana Miljkovic
  • Marko Robnik–Šikonja
  • Nada Lavrač
Conference paper
Part of the Lecture Notes in Computer Science book series (LNCS, volume 11198)


Parkinson’s disease is a neurodegenerative disease affecting people worldwide. Since the reasons for Parkinson’s disease are still unknown and currently there is no cure for the disease, the management of the disease is directed towards handling of the underlying symptoms with antiparkinson medications. In this paper, we present a method for visualization of the patients’ overall status and their antiparkinson medications therapy. The purpose of the proposed visualization method is multi-fold: understanding the clinicians’ decisions for therapy modifications, identification of the underlying guidelines for management of Parkinson’s disease, as well as identifying treatment differences between groups of patients. The resulting patterns of disease progression show that there are differences between male and female patients.


Data mining Parkinson’s disease Disease progression Therapy modifications Visualization 



This work was supported by the PD_manager project, funded within the EU Framework Programme for Research and Innovation Horizon 2020 grant 643706. We acknowledge also the support of the Slovenian Research Agency (research core funding program P2-0103 and project P2-0209).

Data used in the preparation of this article were obtained from the Parkinsons Progression Markers Initiative (PPMI) ( For up-to-date information on the study, visit PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners. Corporate Funding Partners: AbbVie, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, GE Healthcare, GLAXOSMITHKLINE (GSK), Eli Lilly and Company, Lundbeck, Merck, Meso Scale Discovery (MSD), Pfizer Inc, Piramal Imaging, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB. Philanthropic Funding Partners: Golub Capital. List of funding partners can be also found at


  1. 1.
    Blockeel, H., Raedt, L.D., Ramon, J.: Top-down induction of clustering trees. In: Proceedings of the 15th International Conference on Machine Learning, ICML 1998. pp. 55–63 (1998)Google Scholar
  2. 2.
    Dalrymple-Alford, J., et al.: The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19), 1717–1725 (2010)CrossRefGoogle Scholar
  3. 3.
    Ferreira, J., et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 20(1), 5–15 (2013)CrossRefGoogle Scholar
  4. 4.
    Fox, S.H., et al.: The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 26(S3), S2–S41 (2011)CrossRefGoogle Scholar
  5. 5.
    Goetz, C., Luo, S., Wang, L., Tilley, B., LaPelle, N., Stebbins, G.: Handling missing values in the MDS-UPDRS. Mov. Disord. 30(12), 1632–1638 (2015)CrossRefGoogle Scholar
  6. 6.
    Goetz, C., et al.: Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23(15), 2129–2170 (2008)Google Scholar
  7. 7.
    Guthrie, D., Allison, B., Liu, W., Guthrie, L., Wilks, Y.: A closer look at skip-gram modelling. In: Proceedings of the 5th International Conference on Language Resources and Evaluation, LREC 2006. pp. 1–4 (2006)Google Scholar
  8. 8.
    Kosara, R., Miksch, S.: Visualization methods for data analysis and planning in medical applications. Int. J. Med. Inform. 68(1), 141–153 (2002)CrossRefGoogle Scholar
  9. 9.
    Marek, K., et al.: The Parkinson’s progression markers initiative (PPMI). Prog. Neurobiol. 95(4), 629–635 (2011)Google Scholar
  10. 10.
    National Collaborating Centre for Chronic Conditions: Parkinson’s Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians, London (2006)Google Scholar
  11. 11.
    Olanow, W., Watts, R., Koller, W.: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 56(suppl 5), S1–S88 (2001)CrossRefGoogle Scholar
  12. 12.
    Plaisant, C., Milash, B., Rose, A., Widoff, S., Shneiderman, B.: Lifelines: visualizing personal histories. In: Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, pp. 221–227. CHI 1996, ACM, New York, NY, USA (1996)Google Scholar
  13. 13.
    Seppi, K., et al.: The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(S3) (2011)CrossRefGoogle Scholar
  14. 14.
    Struyf, J., Ženko, B., Blockeel, H., Vens, C., Džeroski, S.: CLUS: User’s Manual (2010)Google Scholar
  15. 15.
    Tsanas, A.: Accurate telemonitoring of Parkinsons disease symptom severity using nonlinear speech signal processing and statistical machine learning. Ph.D. thesis, Oxford University, UK (2012)Google Scholar
  16. 16.
    Tsanas, A., Little, M., McSharry, P., Ramig, L.: Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Trans. Biomed. Eng. 57(4), 884–893 (2010)CrossRefGoogle Scholar
  17. 17.
    Tsanas, A., Little, M.A., McSharry, P.E., Ramig, L.O.: Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Trans. Biomed. Eng. 57(4), 884–893 (2010)CrossRefGoogle Scholar
  18. 18.
    Tsanas, A., Little, M.A., McSharry, P.E., Ramig, L.O.: Enhanced classical Dysphonia measures and sparse regression for telemonitoring of Parkinson’s disease progression. In: Proceedings of the IEEE International Conference on Acoustics Speech and Signal Processing, ICASSP 2010, pp. 594–597. IEEE (2010)Google Scholar
  19. 19.
    Tsanas, A., Little, M.A., McSharry, P.E., Spielman, J., Ramig, L.O.: Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Trans. Biomed. Eng. 59(5), 1264–1271 (2012)CrossRefGoogle Scholar
  20. 20.
    Tufte, E.R.: The Visual Display of Quantitative Information. Graphics Press, Cheshire, CT, USA (2001)Google Scholar
  21. 21.
    Valmarska, A., Miljkovic, D., Konitsiotis, S., Gatsios, D., Lavrač, N., Robnik-Šikonja, M.: Symptoms and medications change patterns for Parkinson’s disease patients stratification. Artif. Intell. Med. (2018).
  22. 22.
    Valmarska, A., Miljkovic, D., Lavrač, N., Robnik-Šikonja, M.: Analysis of medications change in Parkinson’s disease progression data. J. Intell. Inf. Syst. 51(2), 301–337 (2018)CrossRefGoogle Scholar
  23. 23.
    Valmarska, A., Miljkovic, D., Robnik-Šikonja, M., Lavrač, N.: Multi-view approach to Parkinson’s disease quality of life data analysis. In: Proceedings of the International Workshop on New Frontiers in Mining Complex Patterns, pp. 163–178. Springer (2016)Google Scholar
  24. 24.
    Visser, M., Marinus, J., Stiggelbout, A.M., Van Hilten, J.J.: Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov. Disord. 19(11), 1306–1312 (2004)CrossRefGoogle Scholar
  25. 25.
    Washburn, R.A., Smith, K.W., Jette, A.M., Janney, C.A.: The physical activity scale for the elderly (PASE): development and evaluation. J. Clin. Epidemiol. 46(2), 153–162 (1993)CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Anita Valmarska
    • 1
    Email author
  • Dragana Miljkovic
    • 1
  • Marko Robnik–Šikonja
    • 3
  • Nada Lavrač
    • 1
    • 2
    • 4
  1. 1.Jožef Stefan InstituteLjubljanaSlovenia
  2. 2.Jožef Stefan International Postgraduate SchoolLjubljanaSlovenia
  3. 3.Faculty of Computer and Information ScienceUniversity of LjubljanaLjubljanaSlovenia
  4. 4.University of Nova GoricaNova GoricaSlovenia

Personalised recommendations